Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
luveltamab tazevibulin + bevacizumab
- Development stage
- Unknown
- Lead developer
- Sutro Biopharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Luveltamab tazevibulin + bevacizumab is a combination therapy in which luveltamab tazevibulin (STRO-002) is an antibody-drug conjugate targeting folate receptor alpha, linked to a cytotoxic payload, while bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). The combination potentially augments antitumor activity by combining targeted cytotoxicity (via luveltamab tazevibulin) with antiangiogenesis (via bevacizumab). Bevacizumab is approved for several cancers, including ovarian cancer; luveltamab tazevibulin is under clinical investigation, mainly for ovarian and endometrial cancers. This combination is evaluated for solid tumors expressing folate receptor alpha, especially in gynecologic malignancies.
- Other names
- luveltamab tazevibulinSTRO-002STRO002STRO 002bevacizumab
02
Targets
Beyond the preview
Go deeper on luveltamab tazevibulin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on luveltamab tazevibulin + bevacizumab.